Duke will receive an undisclosed upfront payment from Sermonix, as well as future equity and milestone payments. Sermonix also announced that it secured more than $2 million in a
This decision is supported by the most recent data from the Company's ongoing Phase 1b study evaluating the same "triplet combination" therapy being investigated in the amended Phase
The study found that patients with ALK+ advanced NSCLC treated with first-line Zykadia (ceritinib) had a median progression-free survival (PFS) of 16.6 months (95% confidence interval [CI]: 12.6, 27.2), compared to
Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy. Genentech
Velusetrag is an oral investigational drug in development for the treatment of patients with gastroparesis, and is currently being studied in a large, multinational Phase 2b study in
The goal of the collaboration is to accelerate Purdue’s Nav1.7 sodium ion channel drug candidates utilizing AnaBios’ Phase-X discovery platform to develop treatments for chronic pain. Under the terms
Data from this study is expected to be announced in the first half of 2017. MAT2501 is Matinas BioPharma’s orally-administered, encochleated formulation of the broad spectrum IV-only aminoglycoside
LOJUXTA, marketed as JUXTAPID in the United States, is currently approved by the European Commission as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low
The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA. Amgen Research and Development executive vice president Sean E. Harper, M.D. said: "The
VONVENDI is an on-demand recombinant treatment for adults living with VWD and replaces von Willebrand factor (VWF), one of several types of proteins in the blood that are
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.